Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205

被引:514
作者
Philip, Philip A. [1 ]
Benedetti, Jacqueline
Corless, Christopher L.
Wong, Ralph
O'Reilly, Eileen M.
Flynn, Patrick J.
Rowland, Kendrith M.
Atkins, James N.
Mirtsching, Barry C.
Rivkin, Saul E.
Khorana, Alok A.
Goldman, Bryan
Fenoglio-Preiser, Cecilia M.
Abbruzzese, James L.
Blanke, Charles D.
机构
[1] Wayne State Univ, Karmanos Canc Inst, GI Oncol, Detroit, MI 48201 USA
关键词
GROWTH-FACTOR RECEPTOR; TUMOR AGGRESSIVENESS; CANCER; THERAPY; COMBINATION; CARCINOMA; BLOCKADE;
D O I
10.1200/JCO.2009.25.7550
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with pancreas cancer. This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor. Patients and Methods Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to receive gemcitabine alone or gemcitabine plus cetuximab. The primary end point was overall survival. Secondary end points included progression-free survival, time to treatment failure, objective response, and toxicity. Results A total of 745 eligible patients were accrued. No significant difference was seen between the two arms of the study with respect to the median survival time (6.3 months for the gemcitabine plus cetuximab arm v 5.9 months for the gemcitabine alone arm; hazard ratio = 1.06; 95% CI, 0.91 to 1.23; P = .23, one-sided). Objective responses and progression-free survival were similar in both arms of the study. Although time to treatment failure was longer in patients on gemcitabine plus cetuximab (P = .006), the difference in length of treatment was only 2 weeks longer in the combination arm. Among patients who were studied for tumoral EGFR expression, 90% were positive, with no treatment benefit detected in this patient subset. Conclusion In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone. Alternate targets other than EGFR should be evaluated for new drug development.
引用
收藏
页码:3605 / 3610
页数:6
相关论文
共 17 条
[1]  
Bruns CJ, 2000, CANCER RES, V60, P2926
[2]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[3]   Ora treatment for gastric cancer: new choices, better choices? [J].
Cascinu, Stefanu .
LANCET ONCOLOGY, 2008, 9 (03) :188-189
[4]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[5]   Developments in the systemic therapy of pancreatic cancer [J].
El-Rayes, BF ;
Shields, AF ;
Vaitkevicius, V ;
Philip, PA .
CANCER INVESTIGATION, 2003, 21 (01) :73-86
[6]   Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer [J].
Hochster, Howard S. ;
Haller, Daniel G. ;
de Gramont, Aimery ;
Berlin, Jordan D. ;
Philip, Philip A. ;
Moore, Malcolm J. ;
Ajani, Jaffer A. .
CANCER, 2006, 107 (04) :676-685
[7]   Cancer statistics, 2008 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Hao, Yongping ;
Xu, Jiaquan ;
Murray, Taylor ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2008, 58 (02) :71-96
[8]   EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality [J].
Milano, G. ;
Spano, J-P ;
Leyland-Jones, B. .
BRITISH JOURNAL OF CANCER, 2008, 99 (01) :1-5
[9]   Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].
Moore, Malcolm J. ;
Goldstein, David ;
Hamm, John ;
Figer, Arie ;
Hecht, Joel R. ;
Gallinger, Steven ;
Au, Heather J. ;
Murawa, Pawel ;
Walde, David ;
Wolff, Robert A. ;
Campos, Daniel ;
Lim, Robert ;
Ding, Keyue ;
Clark, Gary ;
Voskoglou-Nomikos, Theodora ;
Ptasynski, Mieke ;
Parulekar, Wendy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966
[10]  
Overholser JP, 2000, CANCER, V89, P74, DOI 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.3.CO